HighTower Advisors LLC Raises Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• HighTower Advisors increased its Thermo Fisher Scientific position by 9.8% in the second quarter, bringing its holdings to 159,181 shares valued at approximately $79.8 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly earnings of $6.03 per share, beating estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The stock opened at $612.75, near its 52-week high of $647.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $619.41, while several firms raised targets to $650. The company also declared a quarterly dividend of $0.47 per share, although insiders have sold $44.1 million of stock over the past three months.

HighTower Advisors LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,181 shares of the medical research company's stock after acquiring an additional 14,180 shares during the period. HighTower Advisors LLC's holdings in Thermo Fisher Scientific were worth $79,807,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in shares of Thermo Fisher Scientific by 49,331.5% during the 2nd quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company's stock worth $141,711,778,000 after purchasing an additional 282,082,924 shares during the period. J. Stern & Co. LLP lifted its position in Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter worth approximately $15,501,867,000. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $382,547,000. Finally, Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $3,072,744,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the business's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company's stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.2%

Shares of Thermo Fisher Scientific stock opened at $612.75 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00. The company has a market capitalization of $226.56 billion, a PE ratio of 32.96, a P/E/G ratio of 2.57 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business has a 50-day moving average of $573.06 and a 200-day moving average of $515.96.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 earnings per share. The company's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Analysts Set New Price Targets

Several analysts recently issued reports on TMO shares. Barclays increased their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Jefferies Financial Group reissued a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, CLSA assumed coverage on Thermo Fisher Scientific in a report on Thursday. They issued an "outperform" rating and a C$748.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.